ACR-368 for high-grade endometrial cancer after prior treatments
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial studies ACR-368 for people with high-grade endometrial cancer that has spread or grown despite at least one prior treatment. It may help by testing whether this drug can better control the cancer after other therapies have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign written consent and agree to trial procedures.
- Your cancer diagnosis must be confirmed on tissue (biopsy/surgery) as high-grade endometrial cancer.
- Your cancer must have spread and gotten worse after at least one prior treatment regimen.
- You must have at least one measurable tumor spot on a recent scan (done within 28 days of starting treatment).
- You must have had prior platinum chemotherapy and prior anti–PD-(L)1 immunotherapy, and not too many treatment lines (no more than 3 lines for some groups, no more than 2 lines for others).
- You may need extra tumor tissue: either a new biopsy (for some study groups) or stored/archive tumor samples (for others).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a combination of immunotherapy (adebrelimab) with chemotherapy (carboplatin and paclitaxel), followed by adebrelimab with or without apatinib (a targeted therapy). It is for people with advanced or first-recurrent endometrial cancer who haven't had prior immunotherapy or certain targeted drugs.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Hear when a new Endometrial Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.